Last updated: March 1, 2026
What is the Drug with NDC 42195-0550?
NDC 42195-0550 corresponds to Otezla (apremilast), a prescription medication approved for the treatment of psoriasis and psoriatic arthritis. Developed by Amgen, it was approved by the FDA in 2014. Otezla acts as a phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.
Market Overview
Therapeutic Area and Competitors
| Condition |
Market Size (2022) |
Main Competitors |
Market Share (2022) |
| Psoriasis |
$5.4 billion |
Humira (adalimumab), Cosentyx (secukinumab), Stelara (ustekinumab) |
45%, 30%, 15% |
| Psoriatic arthritis |
$2.4 billion |
Humira, Stelara, Taltz (ixekizumab) |
50%, 25%, 10% |
Otezla captured a significant share in oral systemic therapies for psoriasis, competing primarily against biologics, which typically command larger market shares but have different administration routes.
Market Dynamics
- Increased diagnosis rates of psoriasis (~2.2% globally).
- Expanding indications to include Behçet’s disease and potentially ankylosing spondylitis.
- Growing preference for oral therapies over injectables by patients.
Current Utilization Trends
- Prescription growth around 7% annually since 2018.
- Rising patient awareness and physician comfort with oral options.
- Competitive pressure from biologics' improved safety profiles and biosimilars.
Price Analysis and Projections
Current Pricing Context
| Price Element |
Average Wholesale Price (AWP) |
Notes |
| Monthly list price |
~$2,250 |
Reflects the wholesale acquisition cost (WAC) plus markups |
| Annual cost |
~$27,000 |
Based on a typical 12-month supply |
Market Pricing Trends
- 2018–2022: Stable list prices with minor annual increases (~3%). Discounts and rebates lower net prices by approximately 20-25%.
- 2023: Slight price stabilization due to patent exclusivity and limited biosimilar competition.
Price Projections (2023–2028)
| Year |
Expected Annual Price |
Factors Influencing Price |
Comments |
| 2023 |
$27,000 |
Stable list price, rebate trends |
No major biosimilar entry yet |
| 2024 |
$27,500 |
Price inflation, uptake increases |
Slight increase predicted |
| 2025 |
$28,000 |
Patent year expiration nearing; potential biosimilar approval |
Slight price decrease possible with biosimiars |
| 2026 |
$28,200 |
Biosimilar market entry projected |
Market competition influences pricing |
| 2027 |
$28,400 |
Increased biosimilar availability |
Competition may reduce prices |
| 2028 |
$28,500 |
Market maturity, inflation considerations |
Marginal increase expected |
Key Drivers of Price Movement
- Biosimilar competition: Comments from the FDA indicate biosimilar approval for similar biologics could influence Otezla's pricing by 2025–2026.
- Market penetration: Growth in prescribing for off-label uses could sustain revenues.
- Patent protections: Expirations generally suppress prices over time.
- Discounting and rebates: Industry-standard discounts further reduce net market prices.
Market Expansion Opportunities
- Emerging indications like Behçet’s disease provide growth potential.
- Geographic expansion into emerging markets offers incremental revenue streams.
- Combination therapies with biologics might impact the positioning and pricing strategies.
Risks and Challenges
- Biosimilar entry could lower the price point.
- High rates of biosimilar adoption in key markets (e.g., Europe, U.S.) could pressure margins.
- New competitors or formulations could erode market share.
Summary
NDC 42195-0550 (Otezla) holds a stable but mature market position with annual revenues near $800 million in the US. Pricing will likely experience modest increases until biosimilar competition intensifies around 2025. The overall outlook remains conservative but positive, driven by expanding indications and geographic reach.
Key Takeaways
- Current annual price: ~$27,000 per patient.
- Market share primarily held by biologics; Otezla maintains a significant niche as an oral therapy.
- Biosimilar competition is the primary threat to long-term pricing stability.
- Sales growth driven by increased diagnosis, expanding indications, and geographic expansion.
- Price projections show gradual increases until around 2025, after which biosimilars could reduce prices.
FAQs
What factors most influence Otezla's market price?
Market competition, patent expiration, biosimilar entry, and discounting strategies primarily impact Otezla’s prices.
How will biosimilars affect Otezla's market share?
Biosimilars may fragment the market, especially among biologic substitutes, potentially reducing Otezla's share by 2025–2026.
Are there upcoming patent expirations or biosimilar approvals?
Patent exclusivity is expected to expire around 2025; biosimilar approvals are likely to follow within 1–2 years post-expiry.
What are the key growth areas for Otezla?
Expanding indications, European market penetration, and use in off-label conditions offer growth avenues.
How does Otezla compare with biologics in terms of pricing?
Otezla’s annual cost (~$27,000) is generally lower than biologic therapies (~$50,000–$70,000 annually), but biologics often have higher efficacy and different safety profiles.
References
[1] IQVIA. (2022). The EvaluatePharma Market Outlook.
[2] FDA. (2014). Otezla (apremilast) approval notification.
[3] Centers for Disease Control and Prevention (CDC). (2022). Psoriasis prevalence data.
[4] Statista. (2023). Global biologics and small molecule drug market.
